IP Library Granted Patent US 7,189,416
Granted Patent B2
US 7,189,416 · App. 10/303,117 · Granted Mar 13, 2007

Method for stable and controlled delivery of (-)-hydroxycitric acid

Assignee: Glykon Technologies Group, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,189,416
App. No.
10/303,117
Granted
Mar 13, 2007
Kind
B2
Abstract

A method for making the potassium, sodium and other hygroscopic salts of (−)-hydroxycitric acid and mixtures thereof workable by initial treatment with a desiccating agent, such as fumed silicon dioxide. These may be further rendered non-hygroscopic and non-reactive in acidic media via subsequent encasement in hydrophobic and acidophobic polymers. The calcium and magnesium salts of (−)-hydroxycitric acid likewise can be rendered nonreactive in acidic media. The resulting products are suitable for tableting, encapsulation and use in other dry media for weight loss, appetite suppression, improvements in fat metabolism and postprandial lipemia and other pharmaceutical purposes. Further, the products of this invention can be made nonreactive as components of acidic liquid drink mixes and snack bars and can be used in the production of controlled release administration formats.

Claims (18)

1. A method for stabilizing the salts of (−)-hydroxycitric acid with fumed silicon dioxide as the desiccating agent whereby said agent is admixed with hydrated (−)-hydroxycitrate to make a granulate which is then treated as a material for further pharmaceutical formulation by encasing the resulting powders consisting of the salts of (−)-hydroxycitric acid in acid resistant hydrophobic polymers to produce (−)-hydroxycitrate granulate resistant to environmental moisture, resistant to lactonization under acid environments and resistant to undesirable binding, said method comprising the steps of:

(1) obtaining a salt of (−)-hydroxycitric acid or a combination of salts of (−)-hydroxycitric acid,

(2) blending said salt or combination of said salts of (−)-hydroxycitric acid with a suitable fumed silicon dioxide, and

(3) blending the resulting material with said acid resistant hydrophobic polymer wherein the polymer is selected from the group consisting of cellulose acetate phthalate, ethyl cellulose, zein, acrylic polymers, hydroxymethylpropylmethyl cellulose phthalate, polyvinyl acetate phthalate, cellulose acetate trimalleate, acrylic polymer plasticizers, polymers of poly lactic acid, polymers of glycolic acid, and mixtures thereof, wherein the encased powder product of steps (1), (2) and (3) is formulated into tablets, capsules, prepared dry drink mixes, prepared acidic liquid drinkable products and acidic edible bars.

2. The method in claim 1 , wherein the desiccating agent is fumed silicon dioxide admixed at the rate of 20–25% by weight of the amount of (−)-hydroxycitrate on a dry weight basis.

3. The method of claim 1 , wherein said salt or combination of said salts of (−)-hydroxycitric acid is further blended with cyclodextrin.

4. The method of claim 1 , wherein said salt or combination of said salts of (−)-hydroxycitric acid is spray dried or freeze dried under a vacuum or processed using a fluid bed dryer prior to formulation into tablets, capsules, prepared dry drink mixes, prepared liquid drinkable products and edible bars.

5. The method of claim 1 , wherein the resulting product is a controlled release formulation.

6. The method of claim 1 , further comprising the steps of administering an effective amount of the resulting product to suppress appetite in a patient in need thereof.

7. The method of claim 1 , further comprising the steps of administering an effective amount of the resulting product to inhibit cytoptasmic citrate lyase in a patient in need thereof.

8. The method of claim 1 , further comprising the steps of administering an effective amount of the resulting product to increase fat metabolism in a patient in need thereof.

9. The method of claim 1 , further comprising the steps of administering an effective amount of the resulting product to induce weight loss in a patient in need thereof.

10. The method of claim 1 , wherein an effective amount of the resulting product is administered to reduce blood lipids and postprandial lipemia in a patient in need thereof.

11. The method of claim 1 , wherein the resulting product is further admixed with pharmaceutical agents and exciplents and formulated into tablets, capsules, prepared dry drink mixes, prepared acidic liquid drinkable products and acidic edible bars.

12. The method of claim 3 , wherein the cyclodextrin is hydroxypropyl cyclodextrin.

13. The method of claim 5 , wherein the controlled release formulation is administered once daily.

14. The method of claim 1 , wherein the desiccating agent is fumed silicon dioxide admixed at the rate of 15–30% by weight of the amount of (−)-hydroxycitrate on a dry weight basis.

15. The method of claim 1 , wherein the desiccating agent is fumed silicon dioxide admixed at the rate of 2–40% by weight of the amount of (−)-hydroxycitrate on a dry weight basis.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2022
From: GLYKON TECHNOLOGIES GROUP, LLC
To: NUTRITION RESEARCH GROUP, LIMITED
Reel/Frame 058559/0645 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 18, 2015
From: FOLEY & LARDNER LLP
To: GLYKON TECHNOLOGIES GROUP, LLC
Reel/Frame 035047/0671 →
SECURITY AGREEMENT Recorded Feb 28, 2011
From: GLYKON TECHNOLOGIES GROUP, LLC
To: FOLEY & LARDNER LLP
Reel/Frame 025858/0828 →
SECURITY AGREEMENT Recorded Jan 27, 2011
From: GLYKON TECHNOLOGIES GROUP, LLC
To: FOLEY & LARDNER LLP
Reel/Frame 025704/0941 →
ASSIGNMENT AND QUITCLAIM Recorded Apr 9, 2007
From: RENAISSANCE HERBS, INC.
To: GLYKON TECHNOLOGIES GROUP, LLC
Reel/Frame 019140/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 1, 2005
From: CLOUATRE, DALLAS L.; CLOUATRE, DANIEL E.; DUNN, JAMES M.
To: GLYKON TECHNOLOGIES GROUP, LLC
Reel/Frame 016332/0107 →
Continuity (1)
Related Publication 20040101555A1 · May 27, 2004